METTL1 and ovarian serous cystadenocarcinoma: Furthermore, the survival curve analysis indicated a significant relationship between the expression of METTL1 and OS and DSS of patients with KIRC, LGG, LIHC, mesothelioma, ovarian serous cystadenocarcinoma, and PCPG.